Advertisement

Patient-related adverse events and device failures associated with commercially available enteral or duodenal self-expanding metal stents: an analysis of the MAUDE database

Published:October 07, 2022DOI:https://doi.org/10.1016/j.gie.2022.10.008

      Background and Aims

      Duodenal stents are widely used to treat patients with malignant gastric outlet obstruction (MGOO), most commonly from pancreatic cancer. The WallFlex (Boston Scientific, Natick, Mass, USA) and Evolution (Cook Endoscopy, Winston-Salem, NC, USA) duodenal stents are in widespread use for treating MGOO. The objective of this study was to analyze device failures and patient-related adverse events reported to the U.S. Food and Drug Administration (FDA) for these 2 stents.

      Methods

      We analyzed postmarketing surveillance data on the WallFlex and Evolution duodenal stents from January 2000 to January 2022 through the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm).

      Results

      One hundred fifty-four MAUDE reports were identified and analyzed, from which 176 device failures and 186 patient-related adverse events were identified. Device-related failures for the WallFlex stent were delivery system failure (15.4%) and failure to activate the stent (13.2%). Device failures for the Evolution stent were failure to activate the stent (16.5%) and delivery system failure (15.3%). Patient-related adverse events for the WallFlex stent were perforation (18.9%), death (6.6%), and hemorrhage (3.8%), whereas patient-related adverse events for the Evolution duodenal stent were obstruction (16.3%), perforation (6.3%), aspiration (3.8%), and fragments of broken delivery system left in the patient (3.8%).

      Conclusions

      Both stents are associated with device failures such as failure to activate the stent, stent migration, and occlusion by tumor growth. Despite high success rates, duodenal stents can be associated with serious device failures and patient-related adverse events.

      Graphical abstract

      Abbreviations:

      FDA (U.S. Food and Drug Administration), MAUDE (Manufacturer and User Facility Device Experience), MGOO (malignant gastric outlet obstruction)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gastrointestinal Endoscopy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ramai D.
        • Facciorusso A.
        • Crinò S.F.
        • et al.
        EUS-guided gastroenteric anastomosis: a first-line approach for gastric outlet obstruction?.
        Endosc Ultrasound. 2021; 10: 404-405
        • Tendler D.A.
        Malignant gastric outlet obstruction: bridging another divide.
        Am J Gastroenterol. 2002; 97: 4-6
        • Larssen L.
        • Medhus A.W.
        • Hauge T.
        Treatment of malignant gastric outlet obstruction with stents: an evaluation of the reported variables for clinical outcome.
        BMC Gastroenterol. 2009; 9: 45
        • Moura E.G.
        • Ferreira F.C.
        • Cheng S.
        • et al.
        Duodenal stenting for malignant gastric outlet obstruction: prospective study.
        World J Gastroenterol. 2012; 18: 938-943
        • Boghossian M.B.
        • Funari M.P.
        • De Moura D.T.H.
        • et al.
        EUS-guided gastroenterostomy versus duodenal stent placement and surgical gastrojejunostomy for the palliation of malignant gastric outlet obstruction: a systematic review and meta-analysis.
        Langenbecks Arch Surg. 2021; 406: 1803-1817
        • Roy A.
        • Kim M.
        • Christein J.
        • et al.
        Stenting versus gastrojejunostomy for management of malignant gastric outlet obstruction: comparison of clinical outcomes and costs.
        Surg Endosc. 2012; 26: 3114-3119
        • Tang S.J.
        Endoscopic stent placement for gastric outlet obstruction.
        VideoGIE. 2013; 1: 133-136
        • Piesman M.
        • Kozarek R.A.
        • Brandabur J.J.
        • et al.
        Improved oral intake after palliative duodenal stenting for malignant obstruction: a prospective multicenter clinical trial.
        Am J Gastroenterol. 2009; 104: 2404-2411
        • Adler D.G.
        • Baron T.H.
        Endoscopic palliation of malignant gastric outlet obstruction using self-expanding metal stents: experience in 36 patients.
        Am J Gastroenterol. 2002; 97: 72-78
        • Van den Berg M.W.
        • Haijtink S.
        • Fockens P.
        • et al.
        First data on the Evolution duodenal stent for palliation of malignant gastric outlet obstruction (DUOLUTION study): a prospective multicenter study.
        Endoscopy. 2013; 45: 174-181
        • Raina H.
        • Patil P.
        • Mehta S.
        Technical and clinical success rates of WallFlex duodenal stents in unresectable malignant gastric outlet obstruction. A retrospective observational study from a tertiary cancer hospital in India.
        Prz Gastroenterol. 2022; 17: 41-46
        • Miwa H.
        • Sugimori K.
        • Kaneko T.
        • et al.
        Clinical outcome of a highly flexible duodenal stent for gastric outlet obstruction: a multicenter prospective study.
        JGH Open. 2020; 4: 729-735